Pay in 4 interest-free payments of $6.73 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
Opioids, for instance, already slow gut motility
Are the side effects worse with tirzepatide
We did some hard things together
An estimated 20% of obese patients have minimal or no response to GLP-1s and around 40% stop treatment after 12 months mostly due to shortages, dosage inconvenience3 and costs
By reframing GLP-1 entry as a risk-management challenge, companies can position themselves not only for approval but for durable success in what will inevitably be a highly competitive and closely monitored market
392 :e085304 doi:10.1136/bmj-2025-085304 Prime Therapeutics
US$ 24.73
US$ 23.93
US$ 25.12
US$ 22.63
US$ 28.25
US$ 21.94
US$ 20.86
